MCP-1 stimulates leukocyte chemotaxis to inflammatory sites, such as rheumatoid arthritis, atherosclerosis and asthma, by use of the MCP-1 receptor, CCR2, a member of the G-protein coupled-seven transmembrane receptor superfamily. These studies identified a family of antagonists, spiropiperidines. One of the more potent compounds blocks MCP-1 binding to CCR2 with a Kd of 60 nM, but it is unable to block binding to CXCR1, CCR1 or CCR3. These compounds were effective inhibitors of chemotaxis toward MCP-1 but were very poor inhibitors of CCR1 mediated chemotaxis. The compounds are effective blockers of MCP-1 driven inhibition of adenylate cyclase, and MCP-1 and MCP-3 driven cytosolic calcium influx; the compounds are not agonists for these pathways. We showed that glutamate-291 (E291) of CCR2 is a critical residue for high affinity binding, and that this residue contributes little to MCP-1 binding to CCR2.
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Due to MCP-1's involvement in pathophysiological inflammatory diseases we initiated a program to discover small molecule antagonists of the MCP-1 receptor. These efforts lead to the identification of several classes of compounds that inhibited MCP-1 binding to its receptor with affinities between 1 and 15 uM; this report details the properties of one class of inhibitors. We examined several of these compounds in detail with regard to binding affinity and antagonist function at several receptor sites. One class, the spiropiperidines, has affinities that range from 60 nM to inactive and has distinct structure activity relationships; we wished to understand the mechanism of action for these compounds and model their interaction with CCR2 receptor. Using several types of function studies, we examined the effect of the compounds on several postreceptor signaling pathways simulated by MCP-1 and another CCR2 ligand, MCP-3. We also examined the effect of certain site-directed receptor mutations on the binding affinity of MCP-1 and several compounds. These studies revealed an unappreciated similarity between binding of compounds to biogenic-amine receptors and their binding to MCP-1 receptor. We have built models of the CCR2 receptor incorporating the mutagenesis data, the spiropiperidine structure activity relationships, and ligand binding and signaling models we have previously presented (27, 28) . These observations provide a model to understand the interaction of the small molecule chemokine antagonists with chemokine receptors and provide a path to the design of better antagonists.
Materials and Methods:
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Compound Synthesis: Spiropiperidines --Briefly, these compounds were prepared by adding the appropriate ortho-lithiated BOC-protected aniline (prepared from the BOCaniline and 2.2 eq. of tert-butyl lithium in THF at -78 °C) to the N-tert-butoxycarbonyl-4-piperidone followed by a spontaneous cyclization under (29) . Yields averaged 60%
after chromatography. Subsequent deprotection of the BOC-protected spirobenzoxazinones using standard procedure (20 eq. TFA in CH 2 Cl 2 ) followed by alkylation with the appropriate alkyl bromide yielded the desired compounds (5 eq.
Hunig's base, 1.2 eq. of the bromide in acetonitrile at reflux, 5 hours. The compounds were purified by column chromatography or by preparative thin-layer chromatography using 5:4:1 hexanes/CH 2 Cl 2 /MeOH mixtures. Each sample was >98 % pure.
Preparation of 3-chlorobenzyl 2-pyrrole carboxylic acid, RS-136270: 2-Trifluoroacetylpyrrole (25 g, 0.12 mol) was combined with sodium hydride (6.2 g, 015 mol) in dimethylformamide (300 mL) at 0°C. 3-Chlorobenzylbromide was added and the resulting mixture was stirred for about 15 h at room temperature. The reaction was quenched with water followed by dilute sodium hydroxide (3M, 80 mL) and stirred for 2 hours. Additional sodium hydroxide was added and the water layer was washed with ether. Addition of 6 M HCl to the aqueous phase until the pH was two resulted in the precipitation of the desired carboxylic acid (RS-136270). The compound was filtered and washed with cold water. The crude acid was dissolved in CH 2 Cl 2 and decolorizing charcoal was added. The mixture was stirred on a steam bath and concentrated to 800 mL. The solution was filtered and placed in a refrigerator for 10 days. Filtration and washing with cold ether then afforded 18 g of the pure carboxylic acid (>95%).
Binding site of Small Molecule MCP-1 Receptor Antagonists -7 rcptmutv4.r.o98 v3. 5 All compounds were characterized by NMR spectroscopy ( 1 H and 13 C), IR spectroscopy, mass spectroscopy, melting point, and elemental analysis; the data were consistent with the desired structure.
Binding Assay: A detailed description of the binding assay is described in a previous manuscript (30) . Briefly, binding was measured using membranes prepared from two cell lines, THP-1 and CCR2-CHL cells. Each competition assay (table 1) The other binding assays reported in Table I pM for wild type bearing cells and 100 pM for cells bearing mutations. Data analysis of these type of competition was performed as in Jarnagin et al. (31) . The buffers used for these experiments as well as the equilibration times and temperatures were identical to those used with THP-1 cells.
Intracellular Signaling and Chemotaxis:
The methods for measurement of intracellular signaling and chemotaxis have been described in detail in our previous paper (32) .
Briefly, cytosolic calcium influx was measured in CCR2-CHL cells loaded with the fluorescent dye Fura-2-AM. Quantitation of signal intensity used the integrated signal intensity for 82 sec. after the addition of chemokine and thus has units of M sec.
Antagonism by various compounds of calcium influx was measured using an approximate ED 50 dose of MCP-1, 3 nM, and an approximate ED 25 dose for MCP-3, 5
nM.
Chemotaxis was measured over 1 hour using THP-1-5X cells in a 96 well Boyden chamber apparatus. Cell migration through the polycarbonate filter was quantified by fluorescent staining using propidium iodide in 0.1% Triton-X100. These assays typically gave stimulated to unstimulated migration of 6 fold, range 4-10 fold, using a maximally effective concentration of MCP-1. Chemotaxis antagonist measurements used 3 nM MCP-1 or RANTES; these concentrations are near the ED 95 attractant concentration for MCP-1 and for RANTES as agonists. The data are expressed by normalization to the uninhibited migration caused by the agonist chemokine. The antagonist was present in both chambers of the Boyden apparatus.
Adenylate cyclase inhibition was measured using a reporter linked gene transcription assay; in which firefly luciferase was attached 3' to a cyclic-AMP response Clones of L1.2 cells bearing a single mutant receptor were further checked after cloning to confirm that each isolated cell line contained DNA encoding the desired mutation. Genomic DNA from the clone was isolated using a QIAamp blood DNA isolation kit (Qiagen GmbH, Hilden Germany). The genomic DNA was used as the template in PCR reactions using primers encoded by the T7 region of the pCDNA3.1 vector and a 3'-primer within pCDNA3.1 vector, 5'-TAGAAGGCACAGTCGAGG. The PCR product was further purified using Geneclean columns (Bio101, LaJolla, CA) and then sequenced. The mutations in the third extracellular loop and at the top of the seventh transmembrane domain were sequenced using a primer that included the receptor stop rcptmutv4.r.o98 v3.5 codon, 5' -CTA CGC GTC GAC TTA TAA ACC AGC CGA G. Immunostaining of Cells: Before every study the expression of the MCP- Statistical analysis of data: The data was analyzed for statistical significance by the use of pKd or pIC50; significance determined using ANOVA is indicated in the tables by "#" (p<0.01 and "##" (p<0.001), meaning significant and highly significant. The use of pKd and pIC50 is justified by our examination of the distribution of Kd and IC50's rcptmutv4.r.o98 v3.5
determined for the experiments of these types (32) ; the data is log-normally distributed, as expected for the ratio definition of Kd.
Molecular Modeling:
The primary sequence of more than 100 G-protien coupled receptors including CCR2 were aligned using the Needleman-Wunsch multi-sequence alignment as implemented in the PILEUP command in GCG (receptors that bind peptides and other lignads were included). The sequences were further aligned manually with special attention to transmembrane regions. The recently published bacteriorhodopsin structure and low-resolution structures of rhodopsin was used as a template for the modeling of human CCR2 receptor (27, 28, 34) . The methods used for building these first models are described elsewhere (35) . Briefly, the appropriate residues of the helices of the rhodopsin template were changed to the corresponding amino acid of the CCR2. The amino acid side chains were energy minimized and placed in a reasonable conformation.
For this study the loops were discarded and only the transmembrane bundle was used in the small molecule antagonist binding site analysis. The final structure was minimized with a limited cycle using the Discover software (Biosym) and CVFF force field. Only a few cycle are used to improve the stereochemistry of the model an to remove the unfavorable clashes.
Results:
Identification They are not agonists for calcium influx, adenylate cyclase inhibition or chemotaxis.
These small molecular weight ligands block all post receptor events and do not distinguish between calcium stimulatory receptor conformations caused by either CCR2 agonist, MCP-1 or MCP-3.
Biogenic amine binding properties of the SP and 2CP class. In spite of the high chemokine receptor specificity exhibited by the spiropiperidine compounds, these rcptmutv4.r.o98 v3.5
compounds are potent α 1 -adrenergic receptor blockers ( Figure 1) ; lower affinities were observed for other types of adrenergic receptors, α 2 and β (not shown). In addition several other GPCR-7TM receptors, the serotonin 5HT1a and mu-opioid receptors for example, also bound SP compounds. In the case of the serotonergic receptors, structures with improved CCR2 affinity had decreased 5HT 1a (Figure 1) . A remarkable property of the SP class is its high affinity for α-adrenergic receptors, particularly α 1a receptors and to a lesser extent α 1d receptors. Affinity at α 1b receptors was much lower (not shown).
Affinity at α 1d sites became less as the compounds had improved affinity on CCR2
( Figure 1 ). Affinity at α 1a receptors also decreased as CCR2 affinity increased;
however, because the α 1a affinity of the initial lead compound, RS-21825 was 5.6 nM the decrease in α 1a affinity was insufficient to eliminate α 1a affinity of the SP compounds. The 2CP class of compounds had no significant affinity for biogenic amine receptors, Figure 1 .
Selection of Residues for Mutagenesis Studies --E291 and D284:
The findings of a strong requirement for a basic nitrogen in the SP class of blockers suggests that an acidic residue on CCR2 might provide part of the interaction site. The alignment of several chemokine receptors (figure 4) highlights an unusual feature of chemokine receptors; chemokine receptors contain an acidic glutamic acid, E291, 1.5-2 turns within transmembrane seven, TM-7. Acidic residues are rare in this position in GPC-7TM receptors (36, 37) . We also noted in our sequence alignment aspartic acid-284, D284. This residue is located two helical turns above and on the same helical face as E291 and is also conserved between chemokine receptors. Thus, we chose to make mutations of CCR2 at glutamic acid-291, E291, and aspartic acid-284, D284. We made mutations to alanine, to eliminate the residues side chain, or to asparagine or glutamine, to remove the charge but maintain the side chain's hydrogen bonding potential.
Creation and Characterization of E291 and D284 Mutants:
The mutant receptors were made in an amino terminal flag-epitope tagged receptor (38) and then transfected into certain basic residues on the MCP-1 surface (30), suggest that D284 or E291 may be a site for receptor ligand interaction with some of the MCP-1 basic residues. A model of this interaction has been presented (30) .
Binding Affinities of Mutants for Small Molecular Weight Antagonists:
The ability of these mutants to bind MCP-1 allowed competition measurements of binding affinity of several of the small molecule antagonists. Figure 6 and the summary data presented in Table II show that the spiropiperidine compounds, RS-102895 and RS-504393, bind extremely poorly when E291 is changed to alanine (affinity reduced by 610 fold) or to glutamine (affinity reduced by 250 fold). These findings suggest that the negative charge of glutamic acid is important since glutamine has similar hydrogen bonding potential as glutamic acid, yet E291Q has significantly reduced binding affinity with RS-504393, 250
fold. In contrast to the spiropiperidine compounds the 2-carboxypyrroles, represented by RS-136270, bind to all of the single acidic amino acid mutant receptors with affinities similar to wild type receptors (figure 6). Together these observations suggest that E291 interacts with the basic nitrogen of SP molecules.
Residue D284 mutants bind SP compounds with affinities that are only very modestly changed from wild type affinities, which is in contrast to the large changes in affinity caused by mutations at residue E291 (table II) . Of the single D284 mutations only the affinity of RS-504393 was significantly affected by the change to alanine; however the magnitude of this mutants' reduction in affinity, 3.9 fold, is small when compared to the magnitude of E291 changes, 610 and 250 fold. Thus it would seem that D284 contributes only very slightly to a SP compound binding pocket. 
Discussion:
Structure-Activity-Relationship of SP Compounds: After identification of the spiropiperidines as CCR2 ligands we were able to define several central features of the SAR of these compounds. The spiro arrangement between a phenyl urethane moiety and a piperidine is one of the striking features. The piperidine ring was di-substituted at the 4-position with a spiro-phenyl urethane system. Ring systems other than piperidine and straight chain substitutions of the piperidine system were inactive or quite reduced in affinity. In all the more potent analogs, the nitrogen was connected via an aliphatic chain to an aromatic system. For the SP class, the aromatic system-binding pocket was tolerant of a wide range of substituents, of a variety of sizes, provided that they were nonpolar. Polar substituents were not well tolerated; this implied a binding pocket with substantial hydrophobicity. This phenyl urethane system was mostly intolerant of substitution, particularly large moieties. The urethane moiety could not be replaced or altered without significant losses in activity. The strength of this structure activity relationship and its defined preference for particular sizes and polarities in different parts of the molecule implies several different steric constraints around the phenyl-urethane portion. The absolute requirement for the urethane system, with the nitrogen bearing a hydrogen, implies the presence of a hydrogen bond partner for the urethane nitrogen in the binding pocket. Possibly, the most significant feature of this structure activity relationship is the absolute requirement for a tertiary nitrogen, preferably contained within a piperidine ring. Alterations of the nitrogen pKa lead to complete loss of binding affinity. These features suggest that the register of the compound within its binding site was controlled by an acid-base interaction. Our starting point of the optimization of these compounds was RS-21825, IC50
11.4 uM, and we were able to make steady improvements by increasing the affinity to RS-504393, IC50 90 nM. The discovery of small molecular weight CCR2 antagonists of several different classes was gratifying; since, when we started this effort no drug-like chemokine receptor antagonist had been revealed. In addition, we and others had suggested that the ligand was too big (8600 Dalton) to allow small molecular weight are not able to promote the conformation necessary to drive chemotaxis. Unlike the ligand derived antagonists, the small molecular weight inhibitors are not able to separate these functions, they block all measured post receptor events and are not agonists. Thus they have no ability to promote CCR2 conformations that can couple to post-receptor pathways. These findings indicate that the small molecular weight antagonists interact with the receptor quite differently than ligand derived antagonists.
Receptor Distribution Within Cells:
The point mutations we made in CCR2 were designed to investigate the role of specific residues in MCP-1 and small molecule antagonist binding; they also, revealed interesting findings regarding GPCR-7TM intracellular sorting. As part of our efforts to characterize each mutant thoroughly, we measured receptor density using two techniques. The correlation between the two measurement methods was weak. We believe that the correlation is affected by the 
Binding of SP and 2-CP Compounds to Biogenic Amine Receptors:
The first identified member of the SP family, RS21825, had been previously synthesized as an α-adrenergic receptor antagonist (29) to be used as a treatment for hypertension. In addition to α 1 -adrenergic receptor affinity, some members of this compound class also had significant affinity to 5HT 1 , α 2 -adrenergic and opioid receptors (not shown). Thus we sought to remove the alpha-adrenergic and biogenic amine receptor binding properties from this class while preserving CCR2 affinity. We were successful at eliminating or significantly reducing the affinities of these compounds for α 1d , 5HT 1a , α 2 and opioid receptors while improving the affinities for CCR2. These results show that differences exist among the binding pockets on these G-protein coupled-seven transmembrane receptors; these differences can be exploited to convert molecules that bind to one class into molecules that bind to another class. However, the fact that these receptors were all from families that bind ligands that are basic amines was very provocative. This finding of a shared basic nitrogen motif and other results (below) formed the basis of our hypothesis of similar ligand binding modes between SP compounds and biogenic amines. rcptmutv4.r.o98 v3.5
Significance of acidic residues --E291 and D284:
The results of our mutagenesis experiments establish that the SP compounds interact with E291 and to a lesser extent with D284. The SP class of antagonists requires a basic nitrogen for high affinity. In addition the SP class has significant affinity for biogenic-amine receptors. These findings suggest that the way in which SP molecules bind to CCR2 may be similar to well characterized binding modes of biogenic amine receptor antagonists (49-51). The distribution of acidic amino acids in CCR2 further stimulated our interest, Figure 4 ; the extracellular loops and transmembrane regions contain only 13 acidic residues. Five of the 13 residues are in an acidic cluster located in the amino terminus of the receptor (This cluster was examined in a previous paper (30) .) parts of this cluster are important for MCP binding but none of it is important for small molecular weight ligand binding (Polsky & Jarangin, unpublished). The alignment of several chemokine receptors, Figure   4 , highlights an unusual feature of chemokine receptors; chemokine receptors contain an acidic glutamic acid 1.5-2 turns within TM-7. Acidic residues are very rare in this position in GPC-7TM receptors (37, 52) .
Model of SP compounds binding to Receptor: Models of GPC-7TM receptors were
constructed based on the low-resolution electron cryomicroscopic data available for rhodopsin (28, 34, 53) and the higher resolution structures of bacteriorhodopsin (27) .
These models predict that E291 of TM-7 is inside the ovoid-helical bundle in a mirror image position to the biogenic amine receptor's critical binding residue, an aspartic acid from TM-3.
This binding interaction is illustrated in figure 7 . 
How Does the Binding of a SP Compound Prevent MCP-1 Interactions with CCR2?
Comparison of the model presented in figure 7 with our model of MCP-1 binding to CCR2 (27) thus, affinity estimates greater than 100 uM were felt to be inaccurate and are not reported. 
